Early Growth Hormone Initiation Leads to Favorable Long-Term Growth Outcomes in Children Born Small for Gestational Age
Authors' conclusion
Early initiation of GH therapy in short children born SGA may be an important contributor to height optimization. The data are reassuring regarding the long-term safety of GH therapy in this population.
Study context
- Population
- Short children born small for gestational age (SGA) treated with growth hormone (GH) as prescribed, NordiNet® International Outcome Study (469 European clinics) and ANSWER Program (207 US clinics); effectiveness analysis in treatment-naïve, prepubertal patientseffectiveness analysis
- Participants
- 3,318 children
- Comparison
- GH initiation at 2 to <4 years vs 4 to <6 years vs ≥6 years
- Outcome
- Improvement in height SD score from baseline
- Follow-up
- 8 years of therapy
Methodological detailsmulticentre, international
- Multicentre
- International
Pooled result
As reported in the abstract
Mean improvement in height SD score from baseline
2 to <4 years
+2.5
mean
4 to <6 years
+2.2
mean
≥6 years
+1.7
mean
2 to <4 years vs 4 to <6 years: P = 0.0054 · 2 to <4 years vs ≥6 years: P < 0.0001
Further pooled results
Age distribution at GH initiation
Safety
- No unexpected safety events were reported
Original publication
Early Growth Hormone Initiation Leads to Favorable Long-Term Growth Outcomes in Children Born Small for Gestational Age. J Clin Endocrinol Metab. Published 5 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →